A lyophilized etoposide submicron emulsion with a high drug loading for intravenous injection: preparation, evaluation, and pharmacokinetics in rats

被引:16
作者
Chen, Hao [1 ]
Shi, Shuai [1 ]
Zhao, Mingming [1 ]
Zhang, Ling [1 ]
He, Haibing [1 ]
Tang, Xing [1 ]
机构
[1] Shenyang Pharmaceut Univ, Coll Pharm, Shenyang 110016, Peoples R China
关键词
Emulsion; etoposide-phospholipid complex; freeze-drying; high drug loading; pharmacokinetics; LIPID EMULSION; DEGRADATION KINETICS; TISSUE DISTRIBUTION; VENOUS IRRITATION; STABILITY; BIOAVAILABILITY; PHARMACOLOGY; TENIPOSIDE; LIPOSOMES; VP-16-213;
D O I
10.3109/03639045.2010.487267
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Objective: To develop a submicron emulsion for etoposide with a high drug loading capacity using a drug-phospholipid complex combined with drug freeze-drying techniques. Methods: An etoposide-phospholipid complex (EPC) was prepared and its structure was confirmed by X-ray diffraction and differential scanning calorimetry analysis. A freeze-drying technique was used to produce lyophilized etoposide emulsions (LEPE), and LEPE was investigated with regard to their appearance, particle size, and zeta potential. The pharmacokinetic study in vivo was determined by the UPLC/MS/MS system. Results: It showed that EPC significantly improved the liposolubility of etoposide, indicating a high drug loading intravenous emulsion could be easily prepared by EPC. Moreover, the obtained loading of etoposide in the submicron emulsion was 3.0 mg/mL, which was three times higher than that of the previous liquid emulsions. The optimum cryoprotectant was trehalose (15%) in freeze-drying test. The median diameter, polydispersity index, and zeta potential of the optimum formulation of LEPE were 226.1 +/- 5.1 nm, 0.107 +/- 0.011, and -36.20 +/- 1.13 mV, respectively. In addition, these parameters had no significant change during 6 months storage at 4 +/- 2 degrees C. The main pharmacokinetic parameters exhibited no significant differences between LEPE and etoposide commercial solution except for area under the concentration-time curve and clearance. Conclusions: The stable etoposide emulsion with a high drug loading was successfully prepared, indicating the amount of excipients such as the oil phase and emulsifiers significantly decreased following administration of the same dose of drug, effectively reducing the metabolism by patients while increasing their compliance. Therefore, LEPE has a great potential for clinical applications.
引用
收藏
页码:1444 / 1453
页数:10
相关论文
共 30 条
  • [1] THE PROTECTIVE EFFECT OF FREE AND MEMBRANE-BOUND CRYOPROTECTANTS DURING FREEZING AND FREEZE-DRYING OF LIPOSOMES
    AUSBORN, M
    SCHREIER, H
    BREZESINSKI, G
    FABIAN, H
    MEYER, HW
    NUHN, P
    [J]. JOURNAL OF CONTROLLED RELEASE, 1994, 30 (02) : 105 - 116
  • [2] DEGRADATION KINETICS OF ETOPOSIDE IN AQUEOUS-SOLUTION
    BEIJNEN, JH
    HOLTHUIS, JJM
    KERKDIJK, HG
    VANDERHOUWEN, OAGJ
    PAALMAN, ACA
    BULT, A
    UNDERBERG, WJM
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1988, 41 (1-2) : 169 - 178
  • [3] THE CLINICAL-PHARMACOLOGY OF ETOPOSIDE AND TENIPOSIDE
    CLARK, PI
    SLEVIN, ML
    [J]. CLINICAL PHARMACOKINETICS, 1987, 12 (04) : 223 - 252
  • [4] PLASMA COMPATIBILITY OF INJECTABLES - COMPARISON OF INTRAVENOUS U-74006F, A 21-AMINOSTEROID ANTIOXIDANT, WITH DILANTIN BRAND OF PARENTERAL PHENYTOIN
    COX, JW
    SAGE, GP
    WYNALDA, MA
    ULRICH, RG
    LARSON, PG
    SU, CC
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1991, 80 (04) : 371 - 375
  • [5] IS VITRIFICATION SUFFICIENT TO PRESERVE LIPOSOMES DURING FREEZE-DRYING
    CROWE, JH
    LESLIE, SB
    CROWE, LM
    [J]. CRYOBIOLOGY, 1994, 31 (04) : 355 - 366
  • [6] GABETTA B, 1987, Patent No. 209038
  • [7] Gao K, 2008, DRUG DEV IND PHARM, V34, P1227, DOI [10.1080/03639040802005057, 10.1080/03639040802005057 ]
  • [8] Design and evaluation of an emulsion vehicle for paclitaxel. II. Suppression of the crystallization of paclitaxel by freeze-drying technique
    Han, Jihong
    Washington, Clive
    Davis, Stanley S.
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2007, 33 (10) : 1151 - 1157
  • [9] HANDE KR, 1992, SEMIN ONCOL, V19, P3
  • [10] Etoposide: Four decades of development of a topoisomerase II inhibitor
    Hande, KR
    [J]. EUROPEAN JOURNAL OF CANCER, 1998, 34 (10) : 1514 - 1521